kabutan

OncoTherapy Science, Inc.(4564) Summary

4564
TSE Growth
OncoTherapy Science, Inc.
29
JPY
0
(0.00%)
Jul 30, 3:30 pm JST
0.19
USD
Jul 30, 2:30 am EDT
Result
PTS
outside of trading hours
29.3
Jul 30, 11:16 pm JST
Summary Chart Historical News Financial Result
PER
PBR
13.4
Yield
ー%
Margin Trading Ratio
4.45
Stock Price
Jul 30, 2025
Opening Jul 30, 9:00 am
29 JPY 0.19 USD
Previous Close Jul 29
29 JPY 0.19 USD
High Jul 30, 9:21 am
30 JPY 0.20 USD
Low Jul 30, 9:22 am
28 JPY 0.18 USD
Volume
8,906,700
Trading Value
0.26B JPY 1.75M USD
VWAP
29.0 JPY 0.2 USD
Minimum Trading Value
2,900 JPY 19 USD
Market Cap
8.83B JPY 0.06B USD
Number of Trades
208
Liquidity & Number of Trades
As of Jul 30, 2025
Liquidity
Mid
1-Year Average
390
1-Year High Aug 1, 2024
5,463
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jul 25, 2025 1,536,200 16,104,500 10.48
Jul 18, 2025 1,549,300 16,356,500 10.56
Jul 11, 2025 1,882,800 15,556,700 8.26
Jul 4, 2025 1,263,500 16,147,700 12.78
Jun 27, 2025 965,600 13,866,500 14.36
Company Profile
OncoTherapy Science, Inc. is a drug discovery venture originating from the Institute of Medical Science at the University of Tokyo. The company's main focus is on cancer gene analysis and the development of cancer therapeutics.
Sector
Pharmaceuticals
OncoTherapy Science, Inc. is a research and development-oriented venture that broadly engages in cancer drug development, from drug discovery research to clinical trials. The company promotes R&D in various areas including small molecule drugs, cancer peptide vaccines, and antibody drugs, with multiple ongoing clinical trials. Through its subsidiary, OncoTherapy Science also conducts large-scale cancer gene analysis tests and research and development of cancer immunotherapy, thus engaging in cancer precision medicine-related businesses. The company aims to realize personalized medicine through these efforts. OncoTherapy Science has established a staged revenue model including upfront payments, milestones, and royalties through partnerships with major pharmaceutical companies. The company is characterized by its long-term approach to research and development. As a result, its financial performance largely depends on the development progress of partnering pharmaceutical companies and the sales status of pharmaceuticals, which may not be reflected in short-term results in many cases.